Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients - PubMed

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients

N Rösler et al. J Neural Transm (Vienna). 2001.

Abstract

Immunoreactivities of total apolipoprotein E (ApoE-IR), amyloid beta peptide(1-42) (Abeta42-IR), interleukin-6 (IL-6-IR), substance P (SPIR) and total tau protein (TTIR) were measured in lumbar cerebrospinal fluid samples of patients with Alzheimer's disease (AD), non-Alzheimer's dementias (NAD), neurological disorders without cognitive impairment (OND) and controls without central nervous system disease using sensitive and specific enzyme immunoassay methods. TTIR was highly significantly increased (P < 0,001) and Abeta42-IR was significantly decreased (P < 0,001 vs. OND/CO, P < 0,03 vs. NAD) in the AD cohort compared with the other diagnostic groups. Significant increases in AD were also found for ApoE-IR (P < 0,001) and IL-6 (P < 0,03), but there was a considerable overlap between groups. In the total AD cohort, SPIR was not significantly changed, but AD patients with late disease onset (>65 years) showed significantly higher values than both early onset patients (<65 years) and controls (P < 0,05). Discriminant function analysis showed that Abeta42-IR (cut-off value 375pg/ml) and TTIR (cut-off value 440 pg/ml) levels contributed most to the group classification of patients. At 85% sensitivity for AD and 100% specificity for controls, the combined evaluation of Abeta42-IR and TTIR in this cross-sectional study resulted in a graph separating AD from non-AD patients with increased specificity of 91% and 75% for AD versus OND and NAD, respectively.

Similar articles

• Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus.

  Lins H, Wichart I, Bancher C, Wallesch CW, Jellinger KA, Rösler N. Lins H, et al. J Neural Transm (Vienna). 2004 Mar;111(3):273-80. doi: 10.1007/s00702-003-0075-x. Epub 2003 Dec 3. J Neural Transm (Vienna). 2004. PMID: 14991454

• Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

  Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Lautner R, et al. JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060. JAMA Psychiatry. 2014. PMID: 25162367

• Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?

  Rösler N, Wichart I, Bancher C, Jellinger KA. Rösler N, et al. J Neural Transm Suppl. 1996;47:259-66. doi: 10.1007/978-3-7091-6892-9_18. J Neural Transm Suppl. 1996. PMID: 8841971

• Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

  Sjögren M, Andreasen N, Blennow K. Sjögren M, et al. Clin Chim Acta. 2003 Jun;332(1-2):1-10. doi: 10.1016/s0009-8981(03)00121-9. Clin Chim Acta. 2003. PMID: 12763273 Review.

• CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.

  Blennow K, Vanmechelen E. Blennow K, et al. Brain Res Bull. 2003 Aug 15;61(3):235-42. doi: 10.1016/s0361-9230(03)00086-8. Brain Res Bull. 2003. PMID: 12909293 Review.

Cited by

• Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

  Randall C, Mosconi L, de Leon M, Glodzik L. Randall C, et al. Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170. Front Biosci (Landmark Ed). 2013. PMID: 23747874 Free PMC article. Review.

• Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

  Blennow K. Blennow K. NeuroRx. 2004 Apr;1(2):213-25. doi: 10.1602/neurorx.1.2.213. NeuroRx. 2004. PMID: 15717022 Free PMC article. Review.

• Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview.

  Brosseron F, Krauthausen M, Kummer M, Heneka MT. Brosseron F, et al. Mol Neurobiol. 2014 Oct;50(2):534-44. doi: 10.1007/s12035-014-8657-1. Epub 2014 Feb 25. Mol Neurobiol. 2014. PMID: 24567119 Free PMC article. Review.

• Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

  Martinez AN, Philipp MT. Martinez AN, et al. J Neurol Neuromedicine. 2016;1(2):29-36. doi: 10.29245/2572.942x/2016/2.1020. J Neurol Neuromedicine. 2016. PMID: 27430034 Free PMC article.

• Prioritizing candidate diseases-related metabolites based on literature and functional similarity.

  Wang Y, Juan L, Peng J, Zang T, Wang Y. Wang Y, et al. BMC Bioinformatics. 2019 Nov 25;20(Suppl 18):574. doi: 10.1186/s12859-019-3127-4. BMC Bioinformatics. 2019. PMID: 31760947 Free PMC article.

References

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal